Overview

A Study to Evaluate the Safety, Tolerability and How YH002 Enters, Moves Through and Exits the Body in Subjects With Advanced Solid Malignancies

Status:
Recruiting
Trial end date:
2023-07-25
Target enrollment:
Participant gender:
Summary
This is an open-label, dose-escalation study of the study drug YH002. The study is designed to determine the safety, tolerability and maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of YH002 in patients with advanced solid Malignancies
Phase:
Phase 1
Details
Lead Sponsor:
Eucure (Beijing) Biopharma Co., Ltd